
|Videos|April 6, 2016
How Renal Function and Comorbidities Affect Dosing for NOACs
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient's renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
Advertisement
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient’s renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Advancing Treatment After CDK4/6 Inhibitor Progression in HR+/HER2– Breast Cancer
2
FDA Approves Etuvetidigene Autotemcel, First Gene Therapy for Wiskott-Aldrich Syndrome
3
AI-Powered Deep Proteomics Enables Early, Non-Imaging Detection of Breast Cancer With MRI-Comparable Accuracy
4
Experts Weigh In on GLP-1 Agonist Use in Pediatric Patients with Obesity
5


















































































































































































































